Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Scancell signs manufacturing agreement for its Moditope anti-cancer platform

The AIM-listed firm said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system
cells
Scancell said it plans to commence a phase I/II clinical trial of Moditope in the first half of 2019

Scancell Holdings Plc (LON:SCLP) has signed an agreement with The PolyPeptide Group for the manufacture of its first Moditope anti-cancer platform, Modi-1-AMPLIVANT.

The AIM-listed firm said that the contract with the independent contract manufacturer of therapeutic peptides was signed at the end of March 2018.

READ: Scancell to work with Dutch firm on first on first product for Moditope cancer immune-therapy platform

The cancer specialist said its Moditope platform acts by stimulating the production of CD4+ T cells, which seek out and kill tumour cells that would otherwise be hidden from the immune system.

Scancell said it plans to commence a phase I/II clinical trial of Modi-1-AMPLIVANT in the first half of 2019 in patients with triple-negative breast cancer, ovarian cancer and sarcomas.

Cliff Holloway, CEO of Scancell, said: “Commencing GMP manufacture is an important step in the development of our first Moditope product and is key to moving this novel therapy into the clinic in the first half of 2019.”

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Newswire
February 08 2018

Related Articles

couple in bed
March 14 2018
MED2002 is a rapid onset gel designed for those men where the current pill-based treatments aren’t appropriate, or carry significant side-effects
test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
1506367758_shutterstock_118491940.jpg
September 26 2017
The firm received an order for its clinical research use only (RUO) kits from a large, multinational pharma company

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use